Wednesday, July 19, 2017| Alcon, Cataract Surgery, Contact Lenses & Solutions, Excimer Lasers, FDA Approval/Clearance, Hyperopia, Johnson & Johnson Vision Care, Novartis

EyewireTV — FDA Approves Hyperopia Indication for iDesign; Alcon Sales Increase

In this week’s EyewireTV, the FDA approves a new hyperopia treatment indication for Johnson & Johnson Vision’s Star S4 IR Excimer Laser System and iDesign System; and Alcon sales accelerate in the second quarter, which may have an impact on Novartis’ plans to spin-off the eye care division. Also, British surgeons find 27 contact lenses lodged in a woman’s eye while prepping her for cataract surgery.

Watch Video

Wednesday, July 12, 2017| Blepharoplasty, FDA Approval/Clearance, Glaucoma, Inotek Pharmaceuticals, Intraocular Pressure, IOP, IOPtima, Ocular Therapeutix

EyewireTV — FDA Rejects Dextenza Again; Blepharoplasty System Launched

In this week’s EyewireTV, for the second time, the FDA does not approve Ocular Therapeutix's NDA for Dextenza, citing manufacturing deficiencies; and IOPtima announces the launch of the iLid CO2 laser-assisted blepharoplasty kit. Also, in a phase 2 trial, Inotek Pharmaceuticals’ glaucoma candidate fails to show a clinical advantage in IOP reduction after 4 weeks.

Watch Video

Wednesday, June 28, 2017

EyewireTV — New Glaucoma Laser Procedure; Inflammation NDA Review

In this week’s EyewireTV, Quantel Medical launches the SubCyclo laser procedure, a non-thermal glaucoma treatment that lowers IOP by stimulating the ciliary body and the uveoscleral pathway without destructive effects; and the FDA accepts for review Icon Bioscience's NDA for DEXYCU, an injectable drug candidate for the treatment of inflammation associated with cataract surgery. Also, OD-OS releases its preplanned panretinal photocoagulation (PRP) capability for the Navilas 577s.

Watch Video

Wednesday, June 21, 2017| Business, Clinical Trials, Novartis, Psivida, Retina, Uveitis, Wet AMD

EyewireTV — Novartis Wet AMD Candidate Advances; New Leadership Changes

In this week’s EyewireTV, Novartis’ wet AMD candidate RTH258 (brolucizumab 6 mg) meets the primary and secondary endpoints in two phase 3 trials; and a second phase 3 trial of pSivida's Durasert 3-year treatment for posterior uveitis achieves its primary endpoint by demonstrating a significant reduction in the recurrence of posterior uveitis through 6 months. Also, several leadership changes are announced in the ophthalmology industry.

Watch Video

Wednesday, June 14, 2017

EyewireTV — Eye Care Executives Discuss Recent Changes

In this week’s EyewireTV, eye care executives discuss how recent changes at their companies will improve service and access to technology for physicians and patients.

Watch Video

Wednesday, June 07, 2017| Bausch+Lomb, Capsulotomy/Capsulorrhexis, Carl Zeiss Meditec, Conjunctivitis, FDA Approval/Clearance, Nicox , Valeant, ZEPTO Precision Pulse Capsulotomy

EyewireTV — Zepto Approved in US; B+L Surgical Products for Sale?

In this week’s EyewireTV, Mynosys Cellular Devices receives FDA 510(k) clearance for the Zepto Capsulotomy System; and the FDA approves Nicox’s allergic conjunctivitis drug Zerviate (cetirizine 0.24%), the first topical ocular formulation of the antihistamine cetirizine. Also, Valeant reportedly is in talks to sell its Bausch + Lomb unit’s surgical products business to Carl Zeiss Meditec.

Watch Video

Wednesday, May 31, 2017| Aerie Pharmaceuticals, Beaver-Visitec International, BVI, Clinical Trials, FDA Approval/Clearance, Genentech, Glaucoma, Product Releases

EyewireTV — First FDA Approval for GCA; Phase 3 Roclatan Results

In this week’s EyewireTV, Genentech receives FDA approval for Actemra (tocilizumab) for the treatment of giant cell arteritis, marking the first FDA-approved treatment for the disease; and Aerie Pharmaceuticals reports positive phase 3 topline efficacy results for its fixed-dose combination glaucoma product candidate, Roclatan. Also, Beaver-Visitec International announces the US launch of a long-term dissolvable punctal implant—the Extend 180.

Watch Video

Wednesday, May 24, 2017| American Society of Cataract & Ref Surgeons, ASCRS, Business

EyewireTV — Eye Care Executives Discuss the Future of Ophthalmology

In this week’s EyewireTV, executives at the Ophthalmology Innovation Summit in Los Angeles provide EyewireTV updates on their company’s products and pipeline.

Watch Video

Wednesday, May 17, 2017| Dry Eye, Fluoroquinolones, Nidek, Retinal detachment, RD

EyewireTV — New Dry Eye Guidance; Fluoroquinolones/Retinal Detachment Link

In this week’s EyewireTV, the Tear Film & Ocular Surface Society (TFOS) presents the conclusions and recommendations of the TFOS Dry Eye Workshop II (DEWS II), which may have an impact on the way dry eye disease is diagnosed and examined; and new FDA communication indicates there is no firm evidence suggesting that fluoroquinolone antibiotics may lead to retinal detachment. Also, Nidek launches the SL-2000 Slit Lamp, which aims to provide a clear view of ocular tissue in nearly natural color.

Watch Video

Wednesday, May 10, 2017

EyewireTV - Breaking Industry News from the ASCRS Meeting in Los Angeles

In this week’s EyewireTV, Bausch + Lomb introduces the Stellaris Elite vision enhancement system and Vitesse open-port vitrectomy system; and Zeiss fully integrates the latest generation of Barrett IOL power calculation formulas into the IOLMaster 700. Also, Alcon launches two new cataract surgical technologies—the Intrepid Transformer I/A Handpiece and LenSx Laser SoftFit Patient Interface options.

Watch Video

Wednesday, May 03, 2017| AngioVue OCTA system, Clinical Trials, Dry Eye, Inflammation, Kala Pharmaceuticals, optical coherence tomography angiography, OCT angiography, Optovue, Parion Sciences, Shire

EyewireTV - New OCTA Imaging; Shire Acquires Rights to DED Drug Candidate

In this week’s EyewireTV, Optovue releases the AngioVueHD, an update to the AngioVue system that allows for higher-density OCT angiography imaging; and Kala Pharmaceuticals announces positive topline results from its phase 3 clinical trial of KPI-121 1% for postoperative inflammation and pain. Also, Shire and Parion Sciences enter into an agreement granting Shire exclusive global rights to develop and commercialize dry eye disease drug candidate P-321.

Watch Video

Wednesday, April 26, 2017| Allergan, Clinical Trials, Diabetic Retinopathy, FDA Approval/Clearance, Hydrus™ Microstent, Ivantis, Technology

EyewireTV — FDA Clears TrueTear Neurostimulator; IBM Technology Detects DR

In this week’s EyewireTV, Allergan receives marketing authorization from the FDA for the TrueTear Intranasal Tear Neurostimulator, developed to temporarily increase tear production during neurostimulation in adult patients; and IBM releases the results of new research using deep learning and visual analytics technology to advance early detection of diabetic retinopathy. Also, Ivantis receives FDA clearance to initiate a second investigational device exemption clinical trial of the Hydrus Microstent.

Watch Video

Wednesday, April 19, 2017| Aberrometry, Aerie Pharmaceuticals, Clinical Trials, Diabetic macular edema, DME, Diabetic Retinopathy, Excimer Lasers, FDA Approval/Clearance, Glaucoma, Lucentis, Nidek, Ranibizumab

EyewireTV — New Lucentis Approval; Nidek Launches Excimer Laser System

In this week’s EyewireTV, Lucentis (ranibizumab) receives FDA approval for the treatment of diabetic retinopathy in people with or without diabetic macular edema; and Nidek launches the NAVEX Quest M2 Nidek Advanced Vision Excimer Laser System, which incorporates the Quest M2 excimer laser system, the OPD-Scan III aberrometer and corneal topographer, and Final Fit software. Also, Aerie Pharmaceuticals reports 6-month topline safety and efficacy results of its phase 3 clinical trial (Rocket 4) for glaucoma product candidate Rhopressa.

Watch Video

Tuesday, April 11, 2017| Bausch+Lomb, Dry Eye, FDA Approval/Clearance, Imprimis Pharmaceuticals, Phacoemulsification, Stellaris Vision Enhancement System

EyewireTV — FDA Outpaces Europe in Drug Approvals; New Phaco Platform

In this week’s EyewireTV, a study published online in the New England Journal of Medicine reveals that the FDA outpaced the European Medicines Agency in review times and approval of new drugs between 2011 and 2015; and Bausch + Lomb receives FDA 510(k) clearance for the Stellaris Elite vision enhancement system, the company’s next-generation phaco platform. Also, Imprimis Pharmaceuticals enters into a licensing agreement for the exclusive worldwide rights to Klarity, a patented ophthalmic topical solution and gel technology for patients with dry eye disease.

Watch Video

Wednesday, April 05, 2017| , Cataracts

EyewireTV - Ocular Melanoma Trial; Hepatitis C Link to Cataracts

In this week’s EyewireTV, the first cases using a new drug candidate (AU-011; Aura Biosciences) for treating ocular melanoma are performed at Wills Eye Hospital in Philadelphia; the National Eye Institute outlines its Audacious Goals Initiative, which provides recommendations for regenerating retinal ganglion cells. Also, a large population-based study suggests hepatitis C infection may increase the risk of cataracts.

Watch Video
Load More